July 23, 2009

Zometa® Reduces Bone Loss in Men with Prostate Cancer


A single infusion of Zometa® (zoledronic acid) upon initiation of androgen deprivation therapy for prostate cancer reduces bone mineral loss and maintains bone mineral density for 12 months, according to the results of a study published in Cancer.[1]

Hormone therapy for prostate cancer, or androgen deprivation therapy (ADT), involves the suppression of testosterone levels—an approach that may result in loss of bone density and an increased risk of fracture. Studies show that men experience a rapid loss of bone mineral density (BMD) within the first six to 12 months of ADT.

Zometa is a bisphosphonate drug that slows the loss of bone mineral density. Zometa is approved for use with many different types of cancer and has become part of the standard treatment for men with metastatic prostate cancer.

A study conducted in Japan between 2006 and 2007 involved 40 men with hormone-naïve (not previously treated with hormone therapy) prostate cancer that had metastasized to the bones. Twenty men received a single infusion of Zometa on day one of ADT. The other 20 men represented the control group and received no treatment in addition to the ADT. Bone mineral density of the hip and lumbar spine regions was measured at baseline, six, and 12 months.

There was no difference in bone mineral density at baseline; however, at six months, bone mineral density in the lumbar spine area had decreased 4.6% in the control group and increased 5.1% in the Zometa group. By 12 months, there was a statistically significant difference in bone mineral density between the two groups—with a decrease of 8.2% in the control group and an increase of 3.5% in the Zometa group.

The researchers concluded that a single dose of Zometa within the first 12 months of ADT prevents bone loss and increases bone mineral density in men with hormone-naïve prostate cancer.


[1] Satoh T, Kimura M, Matsumoto K, et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma. Cancer. 2009; 115: 3468-3474.

Copyright © 2010 CancerConsultants. All Rights Reserved.

Tags: Uncategorized, Uncategorized